Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 4/20 | 0.34 |
| ▸ | BRAF | P15056 | 4/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776439 | 0.88 | CA2 (0.36) | CA2CA9RAF1BRAFMAPT | |
| SCHEMBL12654530 | 0.76 | CA2 (0.44) | CA2CA9FGFR4MAPK14BRAF | |
| SCHEMBL12654516 | 0.74 | P2RX1 (0.48) | CA2CA9FGFR4P2RX1ALDH1A1 | |
| SCHEMBL16776442 | 0.74 | CA2 (0.36) | CA2CA9RAF1BRAF | |
| SCHEMBL12654400 | 0.73 | P2RX1 (0.46) | CA2CA9FGFR4MAPK14BRAF | |
| SCHEMBL12654660 | 0.73 | FGFR4 (0.46) | FGFR4 | |
| SCHEMBL1820744 | 0.72 | FGFR4 (0.45) | CA2CA9FGFR4P2RX1 | |
| SCHEMBL12654527 | 0.71 | FGFR4 (0.56) | CA2CA9FGFR4 | |
| SCHEMBL12654664 | 0.71 | FGFR4 (0.42) | CA2CA9FGFR4P2RX1 | |
| SCHEMBL12654639 | 0.71 | FGFR4 (0.49) | CA2CA9FGFR4P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA2 4253/4885CA9 4248/4885FGFR4 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.